导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 13.70% | 668/4773 |
| 近一周 | -0.28% | 1015/5465 |
| 近一月 | -4.66% | 3388/5421 |
| 近一季 | -9.45% | 3572/5231 |
| 近半年 | 13.18% | 425/4920 |
| 近一年 | 13.28% | 896/4394 |
| 近两年 | 81.02% | 833/2954 |
| 近三年 | 48.39% | 594/2253 |
| 成立以来 | -9.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.42% 3622/4961 |
47.62% 648/5312 |
- - |
- - |
| 2025 | 28.38% 1486/4813 |
1.01% 1719/3635 |
-1.12% 3116/4076 |
33.50% 1036/4524 |
-3.73% 3325/4813 |
| 2024 | 7.44% 1658/3463 |
-3.04% 1465/2808 |
-1.51% 1071/3014 |
14.01% 2059/3129 |
-1.31% 1652/3463 |
| 2023 | -12.03% 1442/2656 |
6.40% 690/2280 |
-7.76% 1903/2385 |
-5.06% 1275/2515 |
-5.60% 1412/2655 |
| 2022 | -23.56% 1148/2207 |
-18.65% 1368/1919 |
9.68% 272/2016 |
-15.92% 1370/2113 |
1.89% 1100/2208 |
| 2021 | -1.82% 820/1822 |
-6.38% 999/1255 |
12.49% 329/1330 |
-8.73% 1152/1466 |
2.14% 686/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 天弘国证消费100指数增强发起C VS. 长安沪深300非周期A(740101) |